# Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201

> **NCT02075008** · PHASE2 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 270 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** QGE031

## Key facts

- **NCT ID:** NCT02075008
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-03-27
- **Primary completion:** 2016-03-22
- **Final completion:** 2016-03-22
- **Target enrollment:** 270 (ACTUAL)
- **Why stopped:** The study was prematurely terminated after core study CQGE031B2201 failed to meet the primary objective of demonstrating superiority for QGE031 versus placebo.
- **Last updated:** 2017-08-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02075008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02075008, "Long-term Safety Study of QGE031 in Patients With Allergic Asthma Who Completed Study CQGE031B2201". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02075008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*